



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/665,864	09/18/2003	Zhuyin Julie Li	USA V2002/0121 US NP	8381

5487 7590 09/08/2006

ROSS J. OEHLER  
SANOFI-AVENTIS U.S. LLC  
1041 ROUTE 202-206  
MAIL CODE: D303A  
BRIDGEWATER, NJ 08807

EXAMINER

KIM, TAEYOON

ART UNIT	PAPER NUMBER
----------	--------------

1651

DATE MAILED: 09/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/665,864

Applicant(s)

LI ET AL.

Examiner

Taeyoon Kim

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on 13 April 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-25 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-25 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

Claims 1-25 are pending.

Applicant is informed that the current case has been newly assigned to the Examiner.

#### ***Response to Arguments***

Applicant's response filed on April 13, 2006 has been received and entered into the case. All arguments have been fully considered.

Applicant's arguments against 35 U.S.C. § 103 rejection made by the previous Examiner are not persuasive to overcome the rejection.

Applicant argues that the references fail to teach or suggest all the claim limitation and there is no suggestion or motivation to modify or combine reference teachings to produce claimed invention, based on the reasons as follow;

- 1) The method of Decker et al. takes longer incubation time.
- 2) The method of Decker et al. requires temperature control which cannot be miniaturized.
- 3) The claimed invention does not require temperature control.

These are not persuasive because 1) the method of Decker et al. does not take longer incubation time as Applicant pointed out. In fact, Fig. 1 of Decker et al. shows the incubation time for PARP, NAD substrate and an inhibitor takes only 1 hr at 4°C (see also p 1170; Materials and Methods). Applicant's argument that the method of Decker et al. takes overnight or at least more than 7 hours is the total assay duration rather than the incubation duration.

The argument regarding temperature and its miniaturization is moot because they are not claimed in the current application.

Applicant argues that Corominas et al. which is the second reference supporting the 35 U.S.C. §103 rejection in the previous communication does not teach or suggest anything close to the claimed invention and thus does not remedy the deficiencies of Decker et al.

This argument is not persuasive because the teaching of Corominas et al. in support of the method of Decker et al. is a labeled NAD<sup>+</sup>. Corominas et al. disclose NAD<sup>+</sup> can be used as a labeled NAD<sup>+</sup>. The use of labeled NAD<sup>+</sup> is more efficient than the use of a non-labeled NAD<sup>+</sup> in PARP assay because it can be directly detected without employing another step using an anti-poly(ADP-ribose) and a secondary antibody against the anti-poly(ADP-ribose). Therefore, there is a motivation for a person of ordinary skill in the art to use a labeled NAD<sup>+</sup> in the method of Decker et al.

Applicant also argues that Armstrong et al. (the third reference supporting the 35 U.S.C. §103 rejection in the previous communication) teach a different mechanism and a different fluorometric assay from the claimed invention.

The Examiner agrees with Applicant that the mechanism and assay system utilized by Armstrong et al. are different from the claimed invention. However, it is not the whole teaching of Armstrong et al. used in the combination with the method of Decker et al. in view of Corominas et al. The subject matter would have been adopted from this reference by Decker et al. in view of Corominas et al. is a fluorescence-labeled

NAD+. Applicant's argument regarding a different mechanism and different assay are not applicable to this rejection.

Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill at the time the invention was made.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

1. Claims 1-25 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Decker et al. in view of Corominas et al. and Armstrong et al.

Decker discloses a PARP inhibition assay which differs from that recited in the claims in that Decker does not use fluorescently labeled NAD in the quantification of enzyme activity. See, e.g., Fig 1, on page 1170. However, Corominas et al. clearly discloses that labeled NAD can be used in the quantification of PARP activity. See, e.g., page 16270, left column. Moreover, Armstrong discloses the use of fluorescently labeled NAD in an assay of ADP-ribosylating enzyme, an assay which detects similar activity to that of both Decker and Corominas. See, e.g., page 28. Thus, the artisan of ordinary skill would have considered it obvious to have used fluorescently labeled NAD in the quantification of enzyme activity in Decker's assay, motivation for such practice being derived from Corominas' disclosure of the suitability of labeled NAD as detection

moiety in PARP assays, and from Armstrong's disclosure of the suitability of fluorescently labeled NAD as a detection moiety in a similar assay of ADP-ribosylating enzyme. Moreover, the selection of known fluorescent moieties, and the determination of suitable linking moieties therefor as recited in the claims under examination, would have been considered obvious in view of the cited references' disclosures of the suitability of using fluorescently labels to detect NAD. A holding of obviousness is therefore required.

2. Claims 1-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Trevigen (Universal Colorimetric PARP Assay kit with histones and coating buffer, 2000) in view of Armstrong et al. (*supra*), Sundberg (Current Opinion in Biotechnology, 2000, 11:47–53) and Human Molecular Genetics (Fluorescence labeling and detection system, 1999; <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hmg.table.479>)

It is noted that although the published date of the Trevigen article is not clearly established, this assay kit utilizing a biotinylated NAD<sup>+</sup> for PARP assay has been disclosed by an article entitled to New Technology (Nature Medicine, 2000, 6:715). Therefore, the Examiner considers the reference as a prior art to the filing date of the current application.

The Trevigen reference teaches a method of determining inhibitors on the activity of PARP comprising steps of incubation of PARP enzyme, an inhibitor, a substrate (biotinylated NAD<sup>+</sup>, DNA, histone), detection of enzymatic activity, and comparison of the measurement (see pages 1-4).

The Trevigen article does not teach the use of fluorescently labeled NAD<sup>+</sup> in an assay.

Armstrong et al. teach the use of fluorescently labeled NAD in an assay of ADP-ribosylating enzyme.

Sundberg teaches fluorescence-based biochemical assays.

It would therefore have been obvious for the person of ordinary skill in the art at the time the invention was made to substitute biotinylated NAD<sup>+</sup> of Trevigen with fluorescently labeled NAD<sup>+</sup> of Armstrong et al. in the method of Trevigen Instruction.

The skilled artisan would have been motivated to make such a modification because Sundberg teach that fluorescence-based detection methods are inherently sensitive due to the short duty cycle of most fluorophores (the fluorescence lifetime of fluorescein is ~4 ns) and consequently high emitted photon fluxes that can be achieved even with modest excitation light sources. This property, combined with the variety of different fluorescence modes that can be exploited to advantage in homogeneous assay formats, makes fluorescence detection highly amenable to many high-throughput screening applications (see page 47, right column).

The person of ordinary skill in the art would have had a reasonable expectation of success in substituting biotinylated NAD<sup>+</sup> with fluorescence-labeld NAD<sup>+</sup> because fluorescence labeling has been well known and practiced in the art.

M.P.E.P. §2144,06 states "In order to rely on equivalence as a rationale supporting an obviousness rejection, the equivalency must be recognized in the prior

Art Unit: 1651

art, and cannot be based on applicant's disclosure or the mere fact that the components at issue are functional or mechanical equivalents. In *re Ruff*, 256 F.2d 590, 118 USPQ 340 (CCPA 1958) (The mere fact that components are claimed as members of a Markush group cannot be relied upon to establish the equivalency of these components. However, an applicant's expressed recognition of an art-recognized or obvious equivalent may be used to refute an argument that such equivalency does not exist.); In *re Scott*, 323 F.2d 1016, 139 USPQ 297 (CCPA 1963)."

Therefore, the substitution of biotinylation from Trevigen Instruction of the fluorescently labeled NAD<sup>+</sup> of Armstrong et al. in an assay of ADP-ribosylating enzyme would have been obvious because Sundberg discloses colorimetric, fluorescent or luminescent read-out as an alternative method for a detection/quantification system (p. 49, right column). Therefore, these may be considered to be art-accepted equivalents.

In addition, various different fluorescence labels such as Texas red, rhodamine, or CyDye are well known equivalents for fluorescent labeling of chemicals as supported by Human Molecular Genetics (*supra*).

One of skill in the art would have been motivated at the time of invention to make this substitution in order to quantify the PARP activity as suggested by Trevigen with a reasonable expectation of success. The claimed subject matter fails to patentably distinguish over the state of the art as represented by the cited references.

Therefore, the invention as a whole would have been *prima facie* obvious to a person of ordinary skill at the time the invention was made.



***Conclusion***


No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taeyoon Kim whose telephone number is 571-272-9041. The examiner can normally be reached on 8:00 am - 4:30 pm ET (Mon-Fri).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Taeyoon Kim  
Patent Examiner  
Art Unit 1651

  
Leon B. Lankford, Jr.  
Primary Examiner  
Art Unit 1651